An Open-label Extension Safety and Efficacy Study of QCZ484 in Hypertensive Patients.

Part of paid clinical trials in Garden Grove, California.

Sponsor
Novartis Pharmaceuticals
Study ID
NCT07543120
Phase
PHASE2
Status
Recruiting

Conditions

  • Hypertension (HTN)

Eligibility Criteria

Sex
ALL
Age
18 Years - N/A
Healthy Volunteers
Not accepted

Interventions

  • QCZ484 — DRUG
    QCZ484 subcutaneous injection, Q6M.

Study Details

The purpose of this extension study is to collect additional safety and efficacy on QCZ484 for hypertensive patients who successfully completed the parent study, CQCZ484A12201 or additional QCZ484 studies as specified in the respective parent study protocols.

Key Dates

Start date
May 7, 2026
Status verified
May 2026
Primary completion
May 31, 2031
Completion
Nov 30, 2031

Study Design

Enrollment
323 participants (estimated)
Allocation
NA
Intervention model
SINGLE_GROUP
Primary purpose
TREATMENT

Arms

  • Experimental: QCZ484
    QCZ484 administered subcutaneously (SC) Q6M

Primary Outcome Measure

Number of participants with AEs [ Time Frame: Up to 66 months ]

Central Contacts

  • Novartis Pharmaceuticals
    1-888-669-6682
  • Novartis Pharmaceuticals
    +41613241111

Locations (6)

FacilityCityStateZIPSite coordinators
NICRs Research CenterGarden GroveCalifornia92844
Maria Murillo
+1 909 206 2454
Mallu Reddy. (PRINCIPAL_INVESTIGATOR)
Entrust Clinical ResearchMiamiFlorida33176
Mariuchi Mayon
Adolfo Cueli (PRINCIPAL_INVESTIGATOR)
Inpatient Research Clinical LLCMiami LakesFlorida33014
Ilianys Marino
+1 786 502 4303
Alexis Gutierrez. (PRINCIPAL_INVESTIGATOR)
Javara ResearchFayettevilleGeorgia30214
Shemeka Williams
229 518 4947
William Cooper. (PRINCIPAL_INVESTIGATOR)
Anderson Medical ResearchFt. WashingtonMaryland20744
Ann-Marie Cobb
Felton Anderson. (PRINCIPAL_INVESTIGATOR)
Monroe Biomedical ResearchMonroeNorth Carolina28112
Maya Patterson
+1 704 283 7359
Awawu Igbinadolor (PRINCIPAL_INVESTIGATOR)

Find similar trials in Garden Grove, CA

Related Studies